Strategic Move by Sobi's Board of Directors
The Board of Directors of Swedish Orphan Biovitrum AB (Sobi) has authorized a significant share repurchase initiative. This decision aligns with the corporate strategy to uphold commitments under long-term incentive programs. Such programs are essential for maintaining motivation among employees and ensuring alignment with shareholder interests.
Details of the Repurchase Authorization
During a recent Annual General Meeting, key motions were passed which included a proposal for the issuance of up to 1,412,788 redeemable and convertible class C shares. This measure is aimed at securing the company’s financial obligations related to its incentive schemes.
Within this framework, the Board has been granted the authority to repurchase all class C shares from existing shareholders. The repurchase can take place on multiple occasions until the next Annual General Meeting and will be executed at a price between the quotient value of the shares, ensuring shareholders benefit fairly from this initiative.
Implementation of the Share Buyback
Currently, the Board of Directors is set to exercise the repurchase option starting from mid-July 2025. This initiative will see all issued class C shares bought back at their quotient value. This translates to an estimated price of approximately SEK 0.55 per share for the repurchased shares. The active repurchase period is scheduled from July 16 to November 7, 2025.
With this buyback plan, Sobi aims to convert these repurchased class C shares into common shares, which will increase the total common shares held by the company significantly. Following the completion of this operation, the number of common shares would rise to 12,790,468, reflecting the company’s initiative to enhance shareholder value.
About Swedish Orphan Biovitrum AB (Sobi)
Sobi is renowned for its commitment to producing innovative biopharmaceutical solutions that improve the quality of life for individuals with rare diseases. Employing around 1,900 staff globally, the company is versatile, operating in diverse regions including Europe, North America, the Middle East, Asia, and Australia. Recent financial reports indicate that Sobi's revenue soared to SEK 26 billion in the last fiscal year, demonstrating the firm’s robust market position and growth trajectory.
Sobi's shares are traded on Nasdaq Stockholm under the ticker STO:SOBI. The company is dedicated to advancing healthcare and providing exceptional services to its stakeholders.
Contact Information
If you wish to reach out to the Sobi Investor Relations Team, you can find more details on their corporate website for direct inquiries.
Gerard Tobin
Head of Investor Relations
Frequently Asked Questions
What is the purpose of Sobi's share repurchase plan?
The repurchase plan aims to ensure the company can fulfill its commitments to long-term incentive programs, providing additional value to shareholders.
How many shares will Sobi repurchase?
Sobi plans to repurchase up to 1,412,788 redeemable and convertible class C shares as part of this initiative.
What price will Sobi pay for the repurchased shares?
The repurchase price is set between 100% and 105% of the quotient value of the shares, approximately SEK 0.55 per share.
When will the repurchase occur?
The repurchase is scheduled to commence on July 16, 2025, and run until November 7, 2025.
How does this impact Sobi's common shares?
Upon completion of the class C share repurchase and conversion, Sobi's common shares will increase from 11,377,680 to approximately 12,790,468 shares.
